NMR-guided and fragment-based design of protein-protein interaction inhibitors. Application to CK2 kinase.

Alexandre Bancet & Isabelle KRIMMⁱ ¹.Team Small molecules for Biological Targets Centre de Recherche en Cancérologie de Lyon UMR CNRS 5286, INSERM 1052, Université Lyon 1, Hôpital Centre Léon Bérard 69008 Lyon

Mail author : isabelle.krimm@univ-lyon1.fr

Fragment-based approaches that rely on the screening of small libraries (thousands of compounds) against purified therapeutic targets are particularly well suited for the design of protein-protein interaction inhibitors. This is mainly due to the fact that protein-protein interfaces consist of discontinuous hot-spots as compared to more conventional protein pockets. Examples of successful application of fragment screening for the discovery of PPI modulators include XIAP/caspase-9, Bcl-2/Bax, and bromodomains.

The design of compounds from initial fragments typically requires structural information, and X-Ray crystallography is the method of choice. Here we will show how NMR combined to docking can be a robust, rapid and efficient approach for fragment screening, fragment growing and for hit to lead optimization. This will be exemplified using kinase CK2 as therapeutic target.

Fragment Linking Strategies for Structure-Based Drug Design Bancet A, Raingeval C, Lomberget T, Le Borgne M, Guichou JF, Krimm I. *J Med Chem.* 2020, 63(20):11420-11435. doi: 10.1021/acs.jmedchem.0c00242

Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors Kufareva I, Bestgen B, Brear P, Prudent R, Laudet B, Moucadel V, Ettaoussi M, Sautel CF, Krimm I, Engel M, Filhol O, Borgne ML, Lomberget T, Cochet C, Abagyan R. *Sci Rep.* 2019, 9(1):15893. doi: 10.1038/s41598-019-52141-5.

1D NMR WaterLOGSY as an efficient method for fragment-based lead discovery. Raingeval C, Cala O, Brion B, Le Borgne M, Hubbard RE, Krimm I. *J Enzyme Inhib Med Chem.* 2019 Dec;34(1):1218-1225. doi: 10.1080/14756366.2019.1636235.

Ligand-Orientation Based Fragment Selection in STD NMR Screening. Cala O, Krimm I. *J Med Chem.* 2015, 58(21):8739-42. doi: 10.1021/acs.jmedchem.5b01114.